Last update Nov. 6, 2022
Very Low Risk
We do not have alternatives for Omalizumab since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Omalizumab is also known as
Omalizumab in other languages or writings:
Omalizumab belongs to these groups or families:
Main tradenames from several countries containing Omalizumab in its composition:
|Oral Bioavail.||0 (Subcut: 62)||%|
|Tmax||168 - 192||hours|
|Theoretical Dose||0.0003 -0.001||mg/Kg/d|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a recombinant humanized IgG1 anti-immunoglobulin E (IgE) monoclonal antibody. It is an immunoglobulin G (IgG) of huge molecular weight that binds with great affinity to IgE, blocking it, forming IgG-IgE complexes of even larger size and molecular weight. It is indicated in the prophylaxis of severe persistent asthma and in the treatment of chronic urticaria. Its use is authorized in children from 6 years of age (EMA 2016, Pediamecum 2015). Subcutaneous administration every 2 to 4 weeks.
Its very high molecular weight explains the negligible or null passage into breast milk observed. (Saito 2020), since molecules of more than 500 - 1,000 Da do not pass into breast milk. (Hale, Almas 2016, Anderson 2016)
No problems have been observed in infants whose mothers have taken it. (Losappio 2020, López 2019, Ensina 2017, González 2017)
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically zero oral bioavailability), which makes it difficult or prevents the passage to the infant's plasma from ingested breast milk, except in premature infants and the immediate neonatal period, when there may be greater intestinal permeability.
Several medical societies, experts authors and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Hale, Lactmed, Türk 2020, Middleton 2020, Whittam 2019, Matro 2018, Anderson 2018 y 2016, Witzel 2014, Pistilli 2013)